AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseAC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate UpdateAC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
AC Immune to Participate in Upcoming Investor ConferencesAC Immune to Participate in Upcoming Investor Conferences
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndromeAC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseAC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
AC Immune to Present at the Jefferies 2024 London Healthcare ConferenceAC Immune to Present at the Jefferies 2024 London Healthcare Conference
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateAC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s DiseaseAC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative ConditionsAC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateAC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s DiseaseAC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateAC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (
NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer’s disease.
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate UpdateAC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
AC Immune Announces Upcoming Presentations at AD/PD™ 2024AC Immune Announces Upcoming Presentations at AD/PD™ 2024
AC Immune to Regain Global Rights to Crenezumab and SemorinemabAC Immune to Regain Global Rights to Crenezumab and Semorinemab
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseasesAC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
AC Immune Announces Pricing of Underwritten Offering of Common SharesAC Immune Announces Pricing of Underwritten Offering of Common Shares
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFOAC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
